Evidence map›Paper›PMID 30144808›Full record

ArticleDiagnostic pathology2018

Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.

Hayriye Tatli Dogan, Merve Kiran, Burak Bilgin, Aydan Kiliçarslan, Mehmet Ali Nahit Sendur, Bülent Yalçin, Arslan Ardiçoglu, Ali Fuat Atmaca, Berrak Gumuskaya

Open access · goldAbstract read
In one paragraph

Article in Diagnostic pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Resistance to cancer immunotherapy in metastatic renal cell carcinoma.Cancer drug resistance (Alhambra, Calif.) · 2020
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hayriye Tatli DoganFaculty of Medicine, Department of Pathology, Ankara Yıldırım Beyazıt University, Ankara, Turkey. hayriyetatli@gmail.com.
Merve KiranDepartment of Pathology, Usak University, Education and Research Hospital, Usak, Turkey.
Burak BilginDepartment of Oncology, Ankara Atatürk Education and Research Hospital, Ankara, Turkey.
Aydan KiliçarslanFaculty of Medicine, Department of Pathology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Mehmet Ali Nahit SendurFaculty of Medicine, Department of Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Bülent YalçinFaculty of Medicine, Department of Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Arslan ArdiçogluFaculty of Medicine, Department of Urology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Ali Fuat AtmacaFaculty of Medicine, Department of Urology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Berrak GumuskayaFaculty of Medicine, Department of Pathology, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
Ankara Yıldırım Beyazıt University · TRAnkara Atatürk Eğitim ve Araştırma Hastanesi · TRUsak University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundClear cell renal cell carcinoma (ccRCC) is the most common renal malignancy. Hypoxia-inducible factors, HIF-1α and HIF-2α, are expressed in the majority of ccRCC. Targeting immune checkpoints with the blockade of PD-1 and its ligand PD-L1 reorganizes T-cell activity in tumor microenvironment and provides important antitumor responses. PD-L1 upregulation has been found to be hypoxia-inducible factor (HIF) dependent. Our aim is to demonstrate the association between PD-L1 and HIF expression and to reveal the role of PD-L1 in prognosis and its association with tumor microenvironment.

methodsSurgical specimens from 145 patients diagnosed with ccRCC, who had undergone radical or partial nephrectomy, were retrospectively analyzed. Immunohistochemistry on tissue microarrays (TMA) was performed to demonstrate expressions of PD-L1, HIF-1α, and HIF-2α in tumor cells and PD-1, CD4, and CD8 in lymphocytes to assess lymphocyte density in tumor microenvironment.

resultsPD-L1 tumor cell expression was detected in 20/125 (13.8%) cases, which correlated with higher levels of PD-1, CD4, CD8 and HIF-2α expression. Low or high expression of HIF-1α was similar in PD-L1-positive cases. When PD-L1-positive cases were compared with negative ones, there was no significant difference in terms of prognostic factors. However, the number of WHO/ISUP grade 3-4 tumors was significantly higher in PD-L1-positive cases than in negative ones.

conclusionPD-L1 tumor cell expression is strongly associated with increased HIF-2α expression and presence of dense lymphocytic infiltration in ccRCCs. Our findings confirm that PD-L1 positivity is associated with high ISUP nucleolar grade. The association between PD-L1, HIF, and lymphocyte density in tumor microenvironment must be clarified and especially taken into account in combination treatment.

Indexed as

Tumor MicroenvironmentAdultAgedAged, 80 and overB7-H1 AntigenBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCarcinoma, Renal CellEndothelial PAS Domain-Containing Protein 1FemaleHumansHypoxia-Inducible Factor 1, alpha SubunitImmunohistochemistryKidney NeoplasmsLymphocytes, Tumor-InfiltratingMaleB7-H1 AntigenBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCD274 protein, humanEndothelial PAS Domain-Containing Protein 1HIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitHIFPD-1PD-L1Renal cell carcinoma

Identifiers

PMID30144808
PMCPMC6109459
OpenAlexW2888702013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.